Adaptive Biotechnologies IPO: Five things to know

Sarah Toy
Adaptive Biotechnologies IPO: Five things to know

Shares of Adaptive Biotechnologies Corp. rocketed in their public debut Thursday, as investors flocked to the life-sciences research company that’s looking to the immune system to cure the world’s ills. The $18-to$19 estimate was already a boost from the company’s original pricing range of between $15 and $17 a share. Adaptive, a life-sciences research and clinical diagnostics company, believes data from the immune system is the key to diagnosing and treating diseases.